Story
Silo Pharma Stock Plummets 22% on Dilutive Private Placement Deal
Summary
Shares of the biopharmaceutical company fell sharply after it announced an agreement to sell shares and warrants in a private placement that could raise up to $11.7 million, diluting existing shareholders' equity.
Shares of Silo Pharma Inc. (NASDAQ:SILO) plummeted on Friday after the developmental-stage biopharmaceutical company announced a private placement agreement that could raise up to $11.7 million. The deal, which includes the issuance of new shares and warrants, will dilute the ownership stake of existing shareholders.
Details of the Offering
Silo Pharma entered into definitive agreements to sell 619,965 shares of its common stock at a purchase price of $6.452 per share. The offering, priced "at-the-market" under Nasdaq rules, also includes two series of warrants (Series A-3 and Series A-4) allowing the purchase of up to 619,965 shares each.
The company expects to receive aggregate gross proceeds of approximately $4 million upfront, before deducting placement agent fees and other expenses. An additional $7.7 million could be raised if all warrants are exercised for cash, though the company stated there is no assurance this will occur.
Key terms of the warrants are as follows:
- Exercise Price: $6.21 per share.
- Exercisability: Immediately upon issuance.
- Expiration: The Series A-3 warrants expire five years after the effective date of a resale registration statement, while the Series A-4 warrants expire after eighteen months.
Market Reaction and Dilution
AdInvestors reacted negatively to the announcement, sending Silo Pharma's stock down by 22% in Friday's trading. The sharp decline reflects concerns over the dilutive effect of the new shares and the potential for further dilution if the large number of warrants are exercised in the future.
By increasing the total number of shares outstanding, a private placement reduces the ownership percentage of existing investors. This often puts downward pressure on a company's stock price, as seen in Silo's case.
Use of Proceeds and Context
Silo Pharma intends to use the net proceeds from the offering for working capital and general corporate purposes. The company is focused on developing therapeutics for stress-induced psychiatric disorders, chronic pain, and central nervous system diseases.
H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering. The transaction is expected to close on or about July 10, 2026, subject to customary closing conditions.